GlassScriptPhysician profile
Jason Silverston
NPI 1245498609
$9,017.40
in general payments reported to CMS, 2019-2025
43 companies · $2,017 in 2025
The $2,017 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,344 · 2020: $318 · 2021: $632 · 2022: $1,444 · 2023: $1,389 · 2024: $1,873 · 2025: $2,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,205 · Education: $73.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,205.06 |
| Education | $73.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,119.76 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,119.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $813.12 | 2019-2025 | |
| Corcept Therapeutics | $596.40 | 2019-2025 | Korlym |
| Tandem Diabetes Care, INC. | $573.79 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $422.47 | 2019-2025 | Tymlos |
| Insulet Corporation | $408.83 | 2019-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.98 | 2019-2025 | Jardiance |
| Beta Bionics, INC. | $336.60 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Xeris Pharmaceuticals, INC. | $325.69 | 2021-2025 | Gvoke Hypopen |
| Amgen INC. | $301.14 | 2019-2025 | Tepezza |
| Mannkind Corporation | $253.86 | 2020-2025 | Afrezza |
| Abbott Laboratories | $237.66 | 2020-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $236.07 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $223.25 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $220.32 | 2021-2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $153.89 | 2019-2023 | Unithroid |
| Cequr Corporation | $123.85 | 2023-2025 | Cequr Simplicity |
| Abbvie INC. | $109.54 | 2019-2023 | Synthroid |
| Sequel Med Tech, LLC | $103.31 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $94.24 | 2023-2024 | |
| Antares Pharma, INC. | $93.24 | 2019-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $85.95 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $80.56 | 2019-2025 | Strensiq |
| Madrigal Pharmaceuticals | $68.91 | 2025 | Rezdiffra |
| Medtronic, INC. | $65.48 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
| Neurocrine Biosciences, INC. | $55.52 | 2024 | |
| Companion Medical, INC. | $54.25 | 2019 | |
| Horizon Therapeutics Plc | $46.76 | 2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $46.69 | 2025 | Yorvipath |
| Ibsa Pharma INC. | $45.25 | 2019-2023 | Tirosint, Licart |
| Janssen Pharmaceuticals, INC | $44.28 | 2019 | |
| Janssen Biotech, INC. | $41.90 | 2019-2020 | |
| Valeritas, INC. | $30.30 | 2019 | |
| Almatica Pharma LLC | $17.48 | 2025 | Teriparatide |
| Shire North American Group INC | $17.44 | 2019 | |
| Zealand Pharma US, INC. | $17.21 | 2021 | |
| Exact Sciences Corporation | $16.55 | 2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $15.21 | 2019 | |
| Medtronic Minimed, INC. | $15.03 | 2019 | |
| Acella Pharmaceuticals, LLC | $14.84 | 2025 | NP Thyroid 60 |
| Vivus LLC | $11.66 | 2019 | |
| Recordati_rare_diseases_inc. | $10.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Silverston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.